LUCD

Lucid Diagnostics (LUCD)

About Lucid Diagnostics (LUCD)

Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company was founded by Lishan Aklog on May 8, 2018 and is headquartered in New York, NY.

Details

Daily high

$1.29

Daily low

$1.21

Price at open

$1.24

52 Week High

$1.80

52 Week Low

$0.68

Market cap

136.3M

Dividend yield

0.00%

Volume

827,463

Avg. volume

962,979

P/E ratio

-1.05

Lucid Diagnostics News